X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs IPCA LABS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA IPCA LABS GSK PHARMA/
IPCA LABS
 
P/E (TTM) x 60.0 29.6 203.0% View Chart
P/BV x 11.2 3.5 320.0% View Chart
Dividend Yield % 2.6 0.1 1,918.5%  

Financials

 GSK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
IPCA LABS
Mar-18
GSK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,760695 396.9%   
Low Rs2,040400 510.0%   
Sales per share (Unadj.) Rs339.0260.2 130.3%  
Earnings per share (Unadj.) Rs41.419.0 218.3%  
Cash flow per share (Unadj.) Rs45.933.1 138.9%  
Dividends per share (Unadj.) Rs35.001.00 3,500.0%  
Dividend yield (eoy) %1.50.2 798.7%  
Book value per share (Unadj.) Rs242.9213.0 114.0%  
Shares outstanding (eoy) m84.70126.20 67.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.12.1 336.3%   
Avg P/E ratio x57.928.9 200.7%  
P/CF ratio (eoy) x52.316.6 315.5%  
Price / Book Value ratio x9.92.6 384.3%  
Dividend payout %84.55.3 1,603.2%   
Avg Mkt Cap Rs m203,28069,120 294.1%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m5,2347,359 71.1%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m28,71532,836 87.4%  
Other income Rs m545418 130.5%   
Total revenues Rs m29,26033,254 88.0%   
Gross profit Rs m5,0594,505 112.3%  
Depreciation Rs m3801,777 21.4%   
Interest Rs m2240 0.8%   
Profit before tax Rs m5,2222,905 179.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892511 370.2%   
Profit after tax Rs m3,5082,394 146.5%  
Gross profit margin %17.613.7 128.4%  
Effective tax rate %36.217.6 206.0%   
Net profit margin %12.27.3 167.5%  
BALANCE SHEET DATA
Current assets Rs m21,81519,455 112.1%   
Current liabilities Rs m15,99910,076 158.8%   
Net working cap to sales %20.328.6 70.9%  
Current ratio x1.41.9 70.6%  
Inventory Days Days6498 65.0%  
Debtors Days Days1967 27.9%  
Net fixed assets Rs m12,47520,260 61.6%   
Share capital Rs m847252 335.6%   
"Free" reserves Rs m19,72626,633 74.1%   
Net worth Rs m20,57326,886 76.5%   
Long term debt Rs m62,340 0.3%   
Total assets Rs m39,47541,173 95.9%  
Interest coverage x2,612.013.1 19,946.0%   
Debt to equity ratio x00.1 0.3%  
Sales to assets ratio x0.70.8 91.2%   
Return on assets %8.96.4 139.0%  
Return on equity %17.18.9 191.5%  
Return on capital %26.210.8 243.9%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m56415,642 3.6%   
Fx outflow Rs m7,4294,884 152.1%   
Net fx Rs m-6,86510,759 -63.8%   
CASH FLOW
From Operations Rs m4,7283,411 138.6%  
From Investments Rs m-1,042-1,354 76.9%  
From Financial Activity Rs m-3,066-1,304 235.1%  
Net Cashflow Rs m620753 82.3%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.4 89.5%  
FIIs % 23.8 25.3 94.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.4 88.5%  
Shareholders   102,036 36,892 276.6%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  AJANTA PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 14, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS